Literature DB >> 3409189

Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with stage I disease.

F L Meyskens1, D H Berdeaux, B Parks, T Tong, L Loescher, T E Moon.   

Abstract

The authors have studied the natural history of 377 patients with Stage I cutaneous malignant melanoma followed at the Arizona Cancer Center, Tucson. Two hundred eight patients, or 55%, remained free of metastatic disease after a median follow-up of 30 months. The survival at 5, 8, and 10 years was 69, 65, and 63%, respectively. Natural breakpoints in Breslow thickness for survival occurred at 0.85, 1.95, and 4.00 mm. These are not significantly different from those found by other investigators. A step-down multivariate analysis using the Cox regression model yielded four factors as highly significant in predicting survival: Breslow thickness (P less than 0.001), an age/sex interaction (P = 0.0012), clinical ulceration (P = 0.0039), and a prophylactic node dissection (P = 0.019). No predictive value for a BANS or non-BANS location was detected. These results are discussed in reference to other large series which describe the natural history of cutaneous melanoma.

Entities:  

Mesh:

Year:  1988        PMID: 3409189     DOI: 10.1002/1097-0142(19880915)62:6<1207::aid-cncr2820620628>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Age as a prognostic factor in the malignant melanoma population.

Authors:  P F Austin; C W Cruse; G Lyman; K Schroer; F Glass; D S Reintgen
Journal:  Ann Surg Oncol       Date:  1994-11       Impact factor: 5.344

2.  Time course and pattern of metastasis of cutaneous melanoma differ between men and women.

Authors:  Liljana Mervic
Journal:  PLoS One       Date:  2012-03-06       Impact factor: 3.240

3.  The relationship between risk of death from clinical stage 1 cutaneous melanoma and thickness of primary tumour: no evidence for steps in risk. Scottish Melanoma Group.

Authors:  M Keefe; R M Mackie
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

4.  The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients.

Authors:  A C Häffner; C Garbe; G Burg; P Büttner; C E Orfanos; G Rassner
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.